Tag:
New England Journal of Medicine
Latest Headlines
Latest Headlines
NEJM study: IUDs, implants prevent more unwanted pregnancies
A massive new study has determined that contraceptive implants and intrauterine devices (IUDs) help prevent unwanted pregnancies a lot more than the pill, patch or other ring-type birth control products, MedPage Today reports.
St. Jude, Medtronic gave cash to controversial author's institute
It turns out that St. Jude Medical ($STJ) and Medtronic ($MDT) have both given substantial donations to Dr. Robert Hauser's Minneapolis Heart Institute Foundation, according to a juicy new report in MedCity News.
HIV vaccines: When is a failure actually a success?
The Thai trial, also known as RV144, was published in the NEJM in 2009 and is the subject of a new study, which has tried to unpack just how that protective effect worked.
NEJM: Blame chronic diarrhea on mutated gene
Researchers in Norway believe they've found a gene mutation that may cause chronic diarrhea in certain situations, a first step toward more effectively treating, and someday curing such a condition.
Study: Ghostwriting common at top journals
Up to 10 percent of the articles in the most prestigious medical journals were written by unacknowledged, industry-funded ghostwriters. That's the conclusion of a new study released by the editors of
NEJM: Put comparative effectiveness on drug labels
While the government is busy backpedaling away from the idea that comparative effectiveness research should actually inform treatment decisions, some Stanford Med School researchers want to push
Peto bristles at Vytorin-cancer questions
Sir Richard Peto takes umbrage at the idea that he might skew a statistical analysis to benefit a drugmaker. The eminent Oxford statistician, as you know, recently weighed in on a study that seemed
ALSO NOTED: Dyax to close R&D facility;Nastech sells shares; and much more...
> Dyax says it plans to close its research facility in Belgium as it focuses on commercializing DX-88 to treat hereditary angioedema.
Cardiome's CBO discusses changes at FDA
During a conference call with investors yesterday, Cardiome's President and Chief Business Officer, Doug Janzen, had some interesting thoughts on the
ALSO NOTED: CFOs are pharma's new power players; Progen axes staff in restructuring; MethylGene inks collaboration deal;and muc
> Australia's Progen is laying off workers in a restructuring that includes outsourcing the commercial manufacture of PI-88.
